<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02999646</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 11/16</org_study_id>
    <nct_id>NCT02999646</nct_id>
  </id_info>
  <brief_title>Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC</brief_title>
  <official_title>Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced Head and Neck Squamous Cell Carcinoma. A Single Arm, Open Label, Multicenter Phase II Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maxivax SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maxivax SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine the efficacy of the immunotherapy with MVX-ONCO-1&#xD;
      in patients with advanced head and neck squamous cell carcinoma. MVX-ONCO-1 consists of dead&#xD;
      tumor cells from the patient itself and genetically modified cells within a capsule. The&#xD;
      whole treatment takes 9 weeks. At weeks 1, 2, 3, 4, 6 and 8, the tumor cells are injected&#xD;
      underneath the skin and two capsules are implanted for a week. At weeks 2, 3, 4, 5, 7 and 9&#xD;
      the capsules are removed again. The patients are then followed-up for 5 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with advanced HNSCC after platinum-based palliative chemotherapy have a poor&#xD;
      prognosis, with no well-defined standard treatment and a survival between 6 to 9 months.&#xD;
&#xD;
      MVX-ONCO-1 is a patient specific, cell-based, active immunotherapy, where the patient's&#xD;
      immune response to tumor cells is stimulated and/or increased by triggering an immune&#xD;
      response against the patients' cancer cells.&#xD;
&#xD;
      Rationale for this trial is:&#xD;
&#xD;
        1. HNSCC: there is a clear medical need in this patient population,&#xD;
&#xD;
        2. Relapsing HNSCC often have accessible tumor tissue,&#xD;
&#xD;
        3. HNSCC is considered an immunogenic tumor.&#xD;
&#xD;
      This phase II study is a first step towards a potentially innovative immunotherapy for HNSCC.&#xD;
&#xD;
      MVX-ONCO-1 is composed of:&#xD;
&#xD;
        1. An immune-modulator (GM-CSF: granulocyte-macrophage colony stimulating factor) released&#xD;
           from an immuno-protected, encapsulated, allogeneic, genetically modified cell line&#xD;
           (MVX-1), and&#xD;
&#xD;
        2. Irradiated, autologous tumor cells as source of antigen.&#xD;
&#xD;
      Each treatment consists of two macrocapsules containing the MVX-1 cell line implanted&#xD;
      subcutaneously and lethally irradiated autologous tumor cells injected subcutaneously.&#xD;
      Eligible patients will receive a treatment once weekly starting on week 1 for 4 weeks&#xD;
      followed by two additional treatments 2 weeks apart (total 6 treatments over 8 weeks). Each&#xD;
      pair of macrocapsules is removed after 1 week, and the last implanted capsules are removed in&#xD;
      week 9. The patients are then followed-up for 5 years.&#xD;
&#xD;
      The project has received funding from the European Union's Horizon 2020 research and&#xD;
      innovation programme under grant agreement No 880194.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 25, 2018</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Actual">January 25, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>antitumor immunization MVX-ONCO-1</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival at 26 weeks (OS)</measure>
    <time_frame>at 26 weeks from registration</time_frame>
    <description>The primary endpoint of the trial is Overall Survival (OS) at 26 weeks defined as percentage of patients alive 26 weeks from registration. Patients who are lost to follow-up with a date they were last known to be alive less than 26 weeks after registration will be counted as failures for this endpoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to subsequent therapy (TST)</measure>
    <time_frame>assessed within 5 years</time_frame>
    <description>defined as time from registration until documented start of subsequent therapy. Patients who did not start a subsequent therapy will be censored at the last date they were known to be alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>assessed within 5 years</time_frame>
    <description>defined as time from the date when a patient first meets the criteria for complete response (CR) or partial response (PR) until documented radiologic progression, relapse, or death due to disease progression, whichever occurs first. Patients not having an event at the time of analysis and patients starting a new anticancer therapy in the absence of an event will be censored at the date of their last tumor assessment showing non-progression before starting a new treatment. DOR will only be analyzed in the subgroup of patients achieving CR or PR during trial treatment based on RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>at 6, 13, 26, 39 and 52 weeks</time_frame>
    <description>defined as the proportion of patients having CR or PR at the respective time point after registration plus/minus 1 week at week 6, 13, 26, and plus/minus 2 weeks at week 39 and 52 after registration.&#xD;
The response rate will be analyzed based on RECIST 1.1. CR and PR will only be counted if the response is confirmed at least 4 weeks later</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>at 6, 13, 26, 39 and 52 weeks</time_frame>
    <description>defined as the proportion of patients having CR, PR, or stable disease (SD) at the respective time point after registration plus/minus 1 week at week 6, 13, 26, and plus/minus 2 weeks at week 39 and 52 after registration. The disease control rate will be analyzed based on RECIST 1.1. CR and PR will only be counted if the response is confirmed at least 4 weeks later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response</measure>
    <time_frame>assessed within 5 years</time_frame>
    <description>defined as best response achieved at any time during or after the trial treatment before starting a new anticancer treatment. Best overall response will be analyzed based on RECIST 1.1. CR and PR will only be counted if the response is confirmed at least 4 weeks later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response according to iRECIST (iOR)</measure>
    <time_frame>at 6, 13, 26, 39 and 52 weeks</time_frame>
    <description>defined as any complete response (CR/iCR) or partial response (PR/iPR) according to RECIST1.1 or iRECIST criteria achieved before new anti-cancer treatment is given. Any patient with CR/iCR or PR/iPR as best observed response under trial treatment will be considered as a success; otherwise they will be considered as a failure. Patients without any tumor assessment or with non-evaluable response (NE) under trial treatment will be considered as failures for this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>assessed within 5 years</time_frame>
    <description>defined as the time from registration until progression according to RECIST 1.1 or death from any cause, whichever occurs first. Patients not having an event at the time of analysis and patients starting a new anticancer therapy in the absence of an event will be censored at the date of their last tumor assessment showing non-progression before starting a new treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival according to iRECIST (iPFS)</measure>
    <time_frame>assessed within 5 years</time_frame>
    <description>defined as the time from registration until disease progression according to iRECIST criteria (iPD) or death due to any reason, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS at 6, 13, 26, 39, and 52 weeks</measure>
    <time_frame>at 6, 13, 26, 39, and 52 weeks</time_frame>
    <description>will be estimated using the Kaplan-Meier estimator for PFS at the respective time point after registration plus/minus 1 week at week 6, 13, 26, and plus/minus 2 weeks at week 39 and 52 after registration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>assessed within 5 years</time_frame>
    <description>defined as time from registration until death from any cause. Patients which are still alive will be censored at the date they were last known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS under the first subsequent treatment</measure>
    <time_frame>assessed within 5 years</time_frame>
    <description>defined as the time from start of the first subsequence treatment until progression according to RECIST 1.1 or death from any cause, whichever occurs first. Patients not having an event at the time of analysis and patients starting next line of anticancer therapy in the absence of an event will be censored at the date of their last tumor assessment showing non-progression before starting new treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse and serious adverse events</measure>
    <time_frame>assessed within 5 years</time_frame>
    <description>All adverse events (AE) will be assessed according to NCI CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>MVX-ONCO-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MVX-ONCO-1 vaccine treatment once weekly starting on week 1 for 4 weeks followed by two additional treatments 2 weeks apart (total 6 treatments over 8 weeks). Each treatment consists of two macrocapsules containing the MVX-1 cell line and lethally irradiated autologous tumor cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MVX-ONCO-1</intervention_name>
    <description>Autologous cells: 1 vial containing 4x10^6 irradiated tumor cells Capsules: 2 biocompatible capsules loaded with 8x10^5 MVX-1 cells</description>
    <arm_group_label>MVX-ONCO-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for pre-registration:&#xD;
&#xD;
          -  Written informed consent according to ICH/GCP regulations before pre-registration&#xD;
&#xD;
          -  Histologically confirmed diagnosis of head and neck squamous carcinoma (oral cavity,&#xD;
             pharynx, larynx), Stage III/IV in recurrent or metastatic stage. Patients with local&#xD;
             relapse for whom a curative treatment is available cannot be enrolled. Furthermore,&#xD;
             all patients should have no other therapeutic option left.&#xD;
&#xD;
          -  At least one line of prior anticancer therapy for recurrent or metastatic disease.&#xD;
             Patients with locally advanced disease experiencing local relapse within 6 months of&#xD;
             last dose of curative intended, platinum-based chemo-radiation with or without prior&#xD;
             surgery can also be included.&#xD;
&#xD;
          -  Primary tumor and/or metastasis amenable for partial/total surgery or tap&#xD;
&#xD;
          -  Measurable or evaluable disease according to RECIST 1.1 criteria&#xD;
&#xD;
          -  Patients age ≥ 18 years&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Adequate hematological values: neutrophils ≥1x10^9/L, platelets ≥70x10^9/L&#xD;
&#xD;
          -  Adequate hepatic function: bilirubin ≤2 x ULN; AST and ALT and AP ≤2.5 x ULN (except&#xD;
             for patients with liver metastasis: ≤5 x ULN)&#xD;
&#xD;
          -  Adequate renal function (creatinine clearance &gt;40mL/min/1.73m^2, calculated according&#xD;
             to the corrected formula of Cockcroft-Gault&#xD;
&#xD;
          -  Women with child-bearing potential are using effective contraception, are not pregnant&#xD;
             and agree not to become pregnant after pre-registration, during trial treatment and&#xD;
             during the 6 months thereafter. A negative blood pregnancy test before inclusion into&#xD;
             the trial is required for all women with child-bearing potential&#xD;
&#xD;
          -  Men agree not to father a child during trial treatment and during 6 months thereafter&#xD;
&#xD;
        Exclusion Criteria for pre-registration:&#xD;
&#xD;
          -  Known or suspected CNS metastases or active leptomeningeal disease&#xD;
&#xD;
          -  History of hematologic or primary solid tumor malignancy, unless in remission for at&#xD;
             least 3 years from registration with the exception of T1-2 prostate cancer Gleason&#xD;
             score &lt;6 (PSA&lt;10 ng/mL), adequately treated cervical carcinoma in situ or localized&#xD;
             non-melanoma skin cancer&#xD;
&#xD;
          -  Participated in any other investigational study or received an experimental&#xD;
             therapeutic procedure considered to interfere with the study in the 4 preceding weeks&#xD;
             of the pre-registration&#xD;
&#xD;
          -  Concomitant use of other anti-cancer drugs&#xD;
&#xD;
          -  Planned radiotherapy (other than symptom control)&#xD;
&#xD;
          -  Severe or uncontrolled cardiovascular disease uncontrolled hypertension (sustained&#xD;
             systolic blood pressure &gt; 150 mm Hg and/or diastolic &gt; 100 mm Hg despite&#xD;
             antihypertensive therapy)&#xD;
&#xD;
          -  History of cerebrovascular accident or intracranial hemorrhage within 6 months prior&#xD;
             to pre-registration&#xD;
&#xD;
          -  Any history of HIV&#xD;
&#xD;
          -  Known history of HTLV-1, HTLV-2, or active chronic Hepatitis C or Hepatitis B Virus&#xD;
             infection or any uncontrolled active systemic infection requiring intravenous (iv)&#xD;
             antimicrobial treatment&#xD;
&#xD;
          -  Known severe allergy to reagents in the study product (MVX-ONCO-1)&#xD;
&#xD;
          -  Systemic disease other than cancer that is not controlled by approved medication&#xD;
&#xD;
          -  Patient with active autoimmune disease&#xD;
&#xD;
          -  Chronic immunosuppressive treatment exceeding 20 mg/day of prednisone or an equivalent&#xD;
             corticosteroid. Note: In acute situations prednison exceeding 20mg/day or&#xD;
             equivalent(day is allowed during 7 days)&#xD;
&#xD;
          -  Women who are pregnant or breast feeding&#xD;
&#xD;
          -  Any other serious underlying medical, psychiatric, psychological, familial or&#xD;
             geographical condition, which in the judgment of the investigator may interfere with&#xD;
             the planned staging, treatment and follow-up, affect patient compliance or place the&#xD;
             patient at high risk from treatment-related complications&#xD;
&#xD;
        Inclusion criteria for registration:&#xD;
&#xD;
          -  Primary tumor and/or metastasis amenable for partial/total surgery or tap and&#xD;
             subsequent cell harvest &gt; 26x10^6 cells&#xD;
&#xD;
          -  Measurable or evaluable disease according to RECIST 1.1 criteria&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Baseline QoL forms have been completed&#xD;
&#xD;
          -  Adequate hematological values: neutrophils ≥1x10^9/L, platelets ≥70x10^9/L&#xD;
&#xD;
          -  Adequate hepatic function: bilirubin ≤2 x ULN; AST and ALT and AP ≤ 2.5 x ULN (except&#xD;
             for patients with liver metastasis: ≤5 x ULN)&#xD;
&#xD;
          -  Adequate renal function (creatinine clearance &gt;40 mL/min/1.73m^2, calculated according&#xD;
             to the corrected formula of Cockcroft-Gault&#xD;
&#xD;
          -  Women with child-bearing potential are using effective contraception, are not pregnant&#xD;
             or lactating and agree not to become pregnant after registration, during trial&#xD;
             treatment, and during the 6 months thereafter. A negative blood pregnancy&#xD;
&#xD;
        Exclusion criteria for registration:&#xD;
&#xD;
          -  Known or suspected CNS metastases or active leptomeningeal disease&#xD;
&#xD;
          -  Concomitant use of other anti-cancer drugs&#xD;
&#xD;
          -  Planned radiotherapy (other than symptom control)&#xD;
&#xD;
          -  Any one full cycle of anti-cancer chemotherapy treatment in the 3 preceding weeks of&#xD;
             the registration&#xD;
&#xD;
          -  Systemic disease other than cancer, that is not controlled by approved medication&#xD;
&#xD;
          -  Chronic immunosuppressive treatment exceeding 20 mg/day of prednisone or an equivalent&#xD;
             corticosteroid. Note: In acute situations prednisone exceeding 20 mg/day or equivalent&#xD;
             is allowed during 7 days&#xD;
&#xD;
          -  Any other serious underlying medical, psychiatric, psychological, familial or&#xD;
             geographical condition, which in the judgment of the investigator may interfere with&#xD;
             the planned staging, treatment and follow-up, affect patient compliance or place the&#xD;
             patient at high risk from treatment-related complications&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Michielin, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>CHUV Lausanne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HUG Hôpitaux Universitaires Genève</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois CHUV</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>December 19, 2016</study_first_submitted>
  <study_first_submitted_qc>December 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2016</study_first_posted>
  <last_update_submitted>January 27, 2023</last_update_submitted>
  <last_update_submitted_qc>January 27, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>head and neck squamous cell carcinoma</keyword>
  <keyword>cancer</keyword>
  <keyword>HNSCC</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>MVX-ONCO-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02999646
org study id: SAKK 11/16
nct id: NCT02999646
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
The purpose of this trial is to determine the efficacy of the immunotherapy with MVX-ONCO-1
      in patients with advanced head and neck squamous cell carcinoma. MVX-ONCO-1 consists of dead
      tumor cells from the patient itself and genetically modified cells within a capsule. The
      whole treatment takes 9 weeks. At weeks 1, 2, 3, 4, 6 and 8, the tumor cells are injected
      underneath the skin and two capsules are implanted for a week. At weeks 2, 3, 4, 5, 7 and 9
      the capsules are removed again. The patients are then followed-up for 5 years.
Patients with advanced HNSCC after platinum-based palliative chemotherapy have a poor
      prognosis, with no well-defined standard treatment and a survival between 6 to 9 months.

      MVX-ONCO-1 is a patient specific, cell-based, active immunotherapy, where the patient's
      immune response to tumor cells is stimulated and/or increased by triggering an immune
      response against the patients' cancer cells.

      Rationale for this trial is:

        1. HNSCC: there is a clear medical need in this patient population,

        2. Relapsing HNSCC often have accessible tumor tissue,

        3. HNSCC is considered an immunogenic tumor.

      This phase II study is a first step towards a potentially innovative immunotherapy for HNSCC.

      MVX-ONCO-1 is composed of:

        1. An immune-modulator (GM-CSF: granulocyte-macrophage colony stimulating factor) released
           from an immuno-protected, encapsulated, allogeneic, genetically modified cell line
           (MVX-1), and

        2. Irradiated, autologous tumor cells as source of antigen.

      Each treatment consists of two macrocapsules containing the MVX-1 cell line implanted
      subcutaneously and lethally irradiated autologous tumor cells injected subcutaneously.
      Eligible patients will receive a treatment once weekly starting on week 1 for 4 weeks
      followed by two additional treatments 2 weeks apart (total 6 treatments over 8 weeks). Each
      pair of macrocapsules is removed after 1 week, and the last implanted capsules are removed in
      week 9. The patients are then followed-up for 5 years.

      The project has received funding from the European Union's Horizon 2020 research and
      innovation programme under grant agreement No 880194.
allocation: N/A
intervention model: Single Group Assignment
intervention model description: antitumor immunization MVX-ONCO-1
primary purpose: Treatment
masking: None (Open Label)
measure: Overall Survival at 26 weeks (OS)
time frame: at 26 weeks from registration
description: The primary endpoint of the trial is Overall Survival (OS) at 26 weeks defined as percentage of patients alive 26 weeks from registration. Patients who are lost to follow-up with a date they were last known to be alive less than 26 weeks after registration will be counted as failures for this endpoint.
measure: Time to subsequent therapy (TST)
time frame: assessed within 5 years
description: defined as time from registration until documented start of subsequent therapy. Patients who did not start a subsequent therapy will be censored at the last date they were known to be alive
measure: Duration of response (DOR)
time frame: assessed within 5 years
description: defined as time from the date when a patient first meets the criteria for complete response (CR) or partial response (PR) until documented radiologic progression, relapse, or death due to disease progression, whichever occurs first. Patients not having an event at the time of analysis and patients starting a new anticancer therapy in the absence of an event will be censored at the date of their last tumor assessment showing non-progression before starting a new treatment. DOR will only be analyzed in the subgroup of patients achieving CR or PR during trial treatment based on RECIST 1.1.
measure: Objective response rate (ORR)
time frame: at 6, 13, 26, 39 and 52 weeks
description: defined as the proportion of patients having CR or PR at the respective time point after registration plus/minus 1 week at week 6, 13, 26, and plus/minus 2 weeks at week 39 and 52 after registration.
The response rate will be analyzed based on RECIST 1.1. CR and PR will only be counted if the response is confirmed at least 4 weeks later
measure: Disease control rate (DCR)
time frame: at 6, 13, 26, 39 and 52 weeks
description: defined as the proportion of patients having CR, PR, or stable disease (SD) at the respective time point after registration plus/minus 1 week at week 6, 13, 26, and plus/minus 2 weeks at week 39 and 52 after registration. The disease control rate will be analyzed based on RECIST 1.1. CR and PR will only be counted if the response is confirmed at least 4 weeks later.
measure: Best overall response
time frame: assessed within 5 years
description: defined as best response achieved at any time during or after the trial treatment before starting a new anticancer treatment. Best overall response will be analyzed based on RECIST 1.1. CR and PR will only be counted if the response is confirmed at least 4 weeks later.
measure: Objective response according to iRECIST (iOR)
time frame: at 6, 13, 26, 39 and 52 weeks
description: defined as any complete response (CR/iCR) or partial response (PR/iPR) according to RECIST1.1 or iRECIST criteria achieved before new anti-cancer treatment is given. Any patient with CR/iCR or PR/iPR as best observed response under trial treatment will be considered as a success; otherwise they will be considered as a failure. Patients without any tumor assessment or with non-evaluable response (NE) under trial treatment will be considered as failures for this endpoint.
measure: Progression Free Survival (PFS)
time frame: assessed within 5 years
description: defined as the time from registration until progression according to RECIST 1.1 or death from any cause, whichever occurs first. Patients not having an event at the time of analysis and patients starting a new anticancer therapy in the absence of an event will be censored at the date of their last tumor assessment showing non-progression before starting a new treatment.
measure: Progression-free survival according to iRECIST (iPFS)
time frame: assessed within 5 years
description: defined as the time from registration until disease progression according to iRECIST criteria (iPD) or death due to any reason, whichever occurs first.
measure: PFS at 6, 13, 26, 39, and 52 weeks
time frame: at 6, 13, 26, 39, and 52 weeks
description: will be estimated using the Kaplan-Meier estimator for PFS at the respective time point after registration plus/minus 1 week at week 6, 13, 26, and plus/minus 2 weeks at week 39 and 52 after registration.
measure: OS
time frame: assessed within 5 years
description: defined as time from registration until death from any cause. Patients which are still alive will be censored at the date they were last known to be alive.
measure: PFS under the first subsequent treatment
time frame: assessed within 5 years
description: defined as the time from start of the first subsequence treatment until progression according to RECIST 1.1 or death from any cause, whichever occurs first. Patients not having an event at the time of analysis and patients starting next line of anticancer therapy in the absence of an event will be censored at the date of their last tumor assessment showing non-progression before starting new treatment.
measure: Adverse and serious adverse events
time frame: assessed within 5 years
description: All adverse events (AE) will be assessed according to NCI CTCAE v4.0
arm group label: MVX-ONCO-1
arm group type: Experimental
description: MVX-ONCO-1 vaccine treatment once weekly starting on week 1 for 4 weeks followed by two additional treatments 2 weeks apart (total 6 treatments over 8 weeks). Each treatment consists of two macrocapsules containing the MVX-1 cell line and lethally irradiated autologous tumor cells.
intervention type: Other
intervention name: MVX-ONCO-1
description: Autologous cells: 1 vial containing 4x10^6 irradiated tumor cells Capsules: 2 biocompatible capsules loaded with 8x10^5 MVX-1 cells
arm group label: MVX-ONCO-1
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Olivier Michielin, Prof
role: Study Chair
affiliation: CHUV Lausanne
facility: 
facility: 
facility: 
facility: 
country: Switzerland
responsible party type: Sponsor
mesh term: Carcinoma
mesh term: Carcinoma, Squamous Cell
mesh term: Squamous Cell Carcinoma of Head and Neck
sharing ipd: No